However, treatment with IFN-alpha or ICB has limited effects on patients who are refractory to JAK2 inhibitors, suggesting that there is an unmet need for the treatment of MPN through immunotherapies [100]. The gene discussed is JAK2; the disease is myeloproliferative disorder.